SIK1

Serine/threonine-protein kinase SIK1 · P57059 · SIK1 on Sugi Atlas →

14,118 patent compounds predicted against SIK1, 8,781 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1704876	0.91	10/20
SCHEMBL1705125	0.85	10/20
SCHEMBL1704509	0.82	10/20
SCHEMBL1704785	0.65	10/20
SCHEMBL1704413	0.64	10/20
SCHEMBL1705254	0.62	10/20
SCHEMBL2066261	0.60	10/20
SCHEMBL2067692	0.54	10/20
SCHEMBL1147178	0.56	8/20
SCHEMBL1704743	0.54	7/20
SCHEMBL1147168	0.53	7/20
SCHEMBL1146867	0.52	7/20
SCHEMBL1147002	0.52	7/20
SCHEMBL1147078	0.52	7/20
SCHEMBL1696203	0.46	7/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	6/20
Dasatinib Anhydrous (SCHEMBL8226)	0.98	6/20
Dasatinib Anhydrous (SCHEMBL1704366)	0.97	6/20
Dasatinib Anhydrous (SCHEMBL1705152)	0.97	6/20
Dasatinib Anhydrous (SCHEMBL1363032)	0.93	6/20

Clinical trials — most relevant to SIK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
A Study of CS231295 in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Tumor Kinase Inhibitor Concentrations Measured by PET	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SIK1 binder may also engage these)

Protein	Name	Similarity
Q60670	—	1.000	Q60670 →
Q9R1U5	—	1.000	Q9R1U5 →
Q8K330	—	0.994	Q8K330 →
Q60700	—	0.992	Q60700 →
Q3UIZ8	—	0.992	Q3UIZ8 →
O70405	—	0.992	O70405 →
TESK1	Dual specificity testis-specific protein kinase 1	0.992	landscape →
Q8VDG6	—	0.992	Q8VDG6 →
Q2LGB3	—	0.991	Q2LGB3 →
Q63572	—	0.991	Q63572 →
Q5XIS1	—	0.991	Q5XIS1 →
O70146	—	0.991	O70146 →
Q9WUL6	—	0.991	Q9WUL6 →
Q66HE5	—	0.991	Q66HE5 →
Q8R2S1	—	0.990	Q8R2S1 →
Q8BLR5	—	0.990	Q8BLR5 →
Q68UT7	—	0.990	Q68UT7 →
Q8BZN4	—	0.989	Q8BZN4 →
Q5RA67	—	0.989	Q5RA67 →
Q811H0	—	0.989	Q811H0 →
O94761	—	0.988	O94761 →
Q9Z0E3	—	0.988	Q9Z0E3 →
Q80UE6	—	0.988	Q80UE6 →
Q8C0X8	—	0.988	Q8C0X8 →
Q3ULB5	—	0.988	Q3ULB5 →
Q76I79	—	0.987	Q76I79 →
O95238	—	0.987	O95238 →
DYRK1B	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	0.987	landscape →
O88831	—	0.987	O88831 →
Q8TE77	—	0.987	Q8TE77 →